Healthcare Global Enterprises Ltd (HCG) Q1 FY27 Earnings Call: Guides 21-22% EBITDA Margin by FY29, Payer Mix Improves to 69% Non-Institutional

Healthcare Global Enterprises Ltd held its Q1 FY27 earnings call on August 06, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Headline Performance & Revenue Quality

• Revenue of Rs.6,097 Mn (≈13% YoY) — driven by 11% volume growth and 2% ARPP improvement in Q1 FY 2026-2027, with non-institutional revenue growing 17% YoY.
• Adjusted EBITDA at Rs.1,339 Mn, up 20% YoY — margins expanded 120 bps to 19.4% from 18.2% in Q1 FY 2025-2026, driven by payer mix and revenue quality.
• Payor mix improved to 69% non-institutional — vs 67% in Q2 FY 2025-2026, reflecting a structural shift away from low-margin scheme business.
• Cluster revenue: South +16%, East +22%, West +9% — Maharashtra grew +14% while Gujarat was moderated by a deliberate reduction in low-margin immunology therapy scheme business.
• North Bangalore hospital contributed Rs.67 Mn in its first quarter — with 550+ new registrations and 300+ admissions; peak EBITDA loss occurred in Q1 FY 2026-2027.
• Top-line growth of 13-14% was muted by price-capping headwinds — management acknowledged the headwind but highlighted strong margin expansion trajectory.

Structural Margin Improvement Underway

• Adjusted EBITDA margin of 19.4% in Q1 FY 2026-2027 — expanded 120 bps YoY despite only 2% ARPP growth, driven by payer mix improvement and revenue quality.
• Payer mix improvement identified as the biggest margin lever — institutional (scheme) business declined by 200 bps in Q1 FY 2026-2027, contributing directly to margin expansion.
• CGHS price revision had a 1.5% negative impact on Q1 FY 2026-2027 top line — but a positive (unquantified) impact on margins as the revision improved net realization on those cases.
• 20% of HCG's centers already operate at 24-25% EBITDA margins — providing a proof point for the long-term target as maturing centers and clinical differentiation scale.
• Management targets 21-22% EBITDA margin by FY 2028-2029 — and "24-25% over four to five years (by FY 2030-2031)" per management's stated long-term margin aspiration.
• Operating cash flow before working capital changes was ~Rs.125 Cr in Q1 FY 2026-2027 — with net operating cash flow of ~Rs.70 Cr, reflecting healthy cash generation despite capex ramp.

Bed Additions, Greenfields & Cluster Dynamics

• 121 beds added in Q1 FY 2026-2027 — with a forward plan of 65 beds in FY27, 520 beds in FY28-FY29, and 230 beds in FY30, of which ~60% are brownfield.
• 340 brownfield beds planned across centers — a significant portion expected to be operationalized during the later part of FY 2028-2029; 120 beds identified across six hospitals, with smaller additions of 10-15 beds each at Baroda, Cuttack, and Ranchi.
• Two greenfield projects totaling 180 beds — Whitefield (South cluster) expected by end of FY 2027-2028, and Maharashtra (West cluster) in FY 2028-2029; three greenfield projects in total, with details of the third to be shared later.
• Record quarterly revenues from 16 out of 25 centers in Q1 FY 2026-2027 — three hospitals moved from the Rs.5-10 Cr monthly revenue trajectory to Rs.10+ Cr during the quarter.
• North Bangalore hospital expected to achieve monthly break-even within FY 2026-2027 — with optimal utilization of 60-65% targeted in the third to fourth year of operations; losses to decline from Q2 FY 2026-2027 onward.
• Institutional business in West declined >16% YoY — reflecting a deliberate reduction in low-margin scheme business (immunology therapies) in Gujarat, which muted revenue but expanded margins.

Technology, Talent & Portfolio Repositioning

• Investments in advanced clinical technology — MRI LINAC, tomotherapy, surgical robots, CAR-T cell therapy, bone marrow transplant, theranostics, and precision diagnostics to improve case mix and clinical differentiation.
• 20 oncologists onboarded in recent months — strengthening clinical talent across key centers to support complex procedure growth and multi-disciplinary care.
• Operational excellence initiatives underway — automation and data analytics to optimize labor and fixed costs; dedicated teams for patient experience; technology-enabled clinical and non-clinical productivity improvements including conversion rate optimization and revenue leakage prevention.
• Strategic exit from Milan business completed in Q1 FY 2026-2027 — to sharpen focus on core oncology operations in India.
• Discontinuation of low-margin oncology drugs impacted top line by ~1.5% in Q1 FY 2026-2027 — margin accretive; similar impact expected for Q2-Q3 FY 2026-2027, then declining as replaced by higher-margin products.
• ESOP policy in final approval stages — charge to impact P&L starting Q2 FY 2026-2027.
• M&A remains a focus — management confirmed value-accretive opportunities in new or existing markets are being evaluated.

Capital Allocation, Debt Reduction & Investment

• Q1 FY 2026-2027 total capex of Rs.75 Cr — comprising Rs.35 Cr for growth and Rs.40 Cr for maintenance; annual maintenance capex guided at ~Rs.100 Cr per year.
• Rights issue proceeds of Rs.465 Cr deployed — Rs.170 Cr for debt repayment, Rs.150 Cr to increase shareholding in a facility from 51% to 85%, Rs.50 Cr for expenses, and Rs.95 Cr for general corporate purposes.
• Interest cost declined in Q1 FY 2026-2027 — due to prepayment of Rs.170 Cr of loans from rights issue proceeds; management expects interest cost to be moderated in FY 2026-2027 vs FY 2025-2026.
• Total depreciation and finance cost of ~Rs.110 Cr in Q1 FY 2026-2027 — lease component at ~9% of total, consistent with past trends.
• Sales and marketing expenses increased >20% YoY in Q1 FY 2026-2027 — marketing spend at 2.9% of sales due to North Bangalore launch; expected to normalize to 2.5-2.6% over time.
• Southern cluster facilities have headroom up to 75-80% utilization — providing capacity for growth without immediate greenfield investment in that region.

Revenue Trajectory, Margin Pathway & Risks

• Mid-teens revenue growth guidance reiterated for FY 2026-2027 from existing centers — supported by case mix improvement, occupancy gains, and new greenfield/brownfield additions despite bed expansion CAGR of 8% from FY 2025-2026 to FY 2028-2029.
• Management targets 21-22% EBITDA margin by FY 2028-2029 — and "24-25% over four to five years (by FY 2030-2031)" with maturing centers, payer mix improvement, and clinical differentiation as key levers; period unspecified for the 24-25% target in one reference from management.
• North Bangalore losses to decline from Q2 FY 2026-2027 onward — as clinician onboarding, insurance empanelments, and patient ramp-up progress; monthly break-even expected within FY 2026-2027.
• Discontinuation of low-margin drugs to impact top line by ~1.5% for Q2-Q3 FY 2026-2027 — then marginally decline as replaced by higher-margin products; ESOP charge to begin in Q2 FY 2026-2027.
• Three greenfield projects in the pipeline — details of the third project to be shared later; M&A remains a focus for value-accretive opportunities in new or existing markets.
• Price-capping headwinds and CGHS revision continue to weigh on top-line growth — but management sees margin expansion as the primary value creation driver over the medium term.